NYSE:TMO
307.15
10.57
(3.56%)
Analysis and Opinions about TMO-N
Signal
Opinion
Expert
DON'T BUY
DON'T BUY
January 29, 2020
It's done very well, despite a hiccup in Q3 earnings. TMO is in the news because it makes lab equipment, and trades at 35x earnings. It has a steady growth rate, but they need a strong catalyst to grow at that high multiple.
Show full opinionHide full opinion
It's done very well, despite a hiccup in Q3 earnings. TMO is in the news because it makes lab equipment, and trades at 35x earnings. It has a steady growth rate, but they need a strong catalyst to grow at that high multiple.
DON'T BUY
DON'T BUY
January 17, 2020
A diversified lab equipment and diagnostics company. They also have an industrial component to their business. They are not part of their fund. The earnings multiple for the sector expanded by 20x. Basically, you are paying more for the same company. That's okay for a growth company but you have to execute perfectly. It is one of the safer choices, but he thinks it's a little too rich now.
Show full opinionHide full opinionA diversified lab equipment and diagnostics company. They also have an industrial component to their business. They are not part of their fund. The earnings multiple for the sector expanded by 20x. Basically, you are paying more for the same company. That's okay for a growth company but you have to execute perfectly. It is one of the safer choices, but he thinks it's a little too rich now.
BUY WEAKNESS
BUY WEAKNESS
December 24, 2019
As a medium-term hold. He expects a general pullback in the next couple weeks. TMO will likely fall back to $300, which is the time to buy. If you already own, take some profits. He likes TMO.
Show full opinionHide full opinionAs a medium-term hold. He expects a general pullback in the next couple weeks. TMO will likely fall back to $300, which is the time to buy. If you already own, take some profits. He likes TMO.
BUY WEAKNESS
BUY WEAKNESS
December 11, 2019
He loves this company -- up 300% over five years. They have a lot of recurring revenues in health care devices. It trades at 25 time earnings, so he is thinking it is fair valued. He would like to buy on a market correction.
Show full opinionHide full opinionHe loves this company -- up 300% over five years. They have a lot of recurring revenues in health care devices. It trades at 25 time earnings, so he is thinking it is fair valued. He would like to buy on a market correction.
WAIT
WAIT
October 2, 2019
It is a life sciences tool company. It is a relatively resilient business, but some of their tools also go into other industrial applications. You have to have a positive view on the economy. He suggests caution as the industrial space is slowing in growth. He will wait until he feels the economy has hit bottom and is rising again. Make no mistake though, this is a best in class company.
Show full opinionHide full opinionIt is a life sciences tool company. It is a relatively resilient business, but some of their tools also go into other industrial applications. You have to have a positive view on the economy. He suggests caution as the industrial space is slowing in growth. He will wait until he feels the economy has hit bottom and is rising again. Make no mistake though, this is a best in class company.
TOP PICK
TOP PICK
August 20, 2019
The world's leading scientific instrument maker. They enjoy huge barriers to entry with government customers. They test food and pharma, and have a huge track record. It trades at reasonable valuations. (Analysts’ price target is $309.38)
Show full opinionHide full opinionThe world's leading scientific instrument maker. They enjoy huge barriers to entry with government customers. They test food and pharma, and have a huge track record. It trades at reasonable valuations. (Analysts’ price target is $309.38)
TOP PICK
TOP PICK
February 15, 2019
Biotech and pharmaceutical lab equipment. Recent acquisition lets them get paid for design and manufacturing for any drug or therapy coming down the pipe. Paying down debt in a big way. Will stand to grow very well over the next number of years, as they generate more free cash flow than net income. Yield is 0.27%. (Analysts’ price target is $270.24)
Show full opinionHide full opinionBiotech and pharmaceutical lab equipment. Recent acquisition lets them get paid for design and manufacturing for any drug or therapy coming down the pipe. Paying down debt in a big way. Will stand to grow very well over the next number of years, as they generate more free cash flow than net income. Yield is 0.27%. (Analysts’ price target is $270.24)
BUY
BUY
October 22, 2018
A strong player in scientific equipment that they sell to corporates and universities. They've done a fine job buying and integrating companies. Overall, they've done a great job. Expect more spending in new medicine and treatments as the population ages, a tailwind for them. They're a little expensive though, so keep an eye on their earnings.
A strong player in scientific equipment that they sell to corporates and universities. They've done a fine job buying and integrating companies. Overall, they've done a great job. Expect more spending in new medicine and treatments as the population ages, a tailwind for them. They're a little expensive though, so keep an eye on their earnings.
COMMENT
COMMENT
April 17, 2018
A terrific business providing lab supplies to everyone from government labs to university research labs. A leader in this space. Generates cash. A slight tailwind with Amazon threatening to enter this space, but this threat has receeded a little. TMO is expensive relative to its growth which gives him pause.
A terrific business providing lab supplies to everyone from government labs to university research labs. A leader in this space. Generates cash. A slight tailwind with Amazon threatening to enter this space, but this threat has receeded a little. TMO is expensive relative to its growth which gives him pause.
COMMENT
COMMENT
April 11, 2018
This is a life sciences sector company. Well known company and the chart looks fantastic. The valuation is fair. The only knock is that he would prefer the diversification of an ETF in this space. There is not much yield.
This is a life sciences sector company. Well known company and the chart looks fantastic. The valuation is fair. The only knock is that he would prefer the diversification of an ETF in this space. There is not much yield.
PAST TOP PICK
PAST TOP PICK
November 1, 2017
(A Past Pick Nov 14/16. Up 32%.) Earnings were just out, and the market liked it. Because of where the market is and where the stock is trading, if you are interested in buying, do half now and the other half later.
(A Past Pick Nov 14/16. Up 32%.) Earnings were just out, and the market liked it. Because of where the market is and where the stock is trading, if you are interested in buying, do half now and the other half later.
PARTIAL BUY
PARTIAL BUY
September 21, 2017
Chart shows that for the last 3 years, it has gone up and to the right despite some volatility. If you like the name, you just have to simply buy it. Maybe take half a position and not even worry about it, and then look for an opportunity to buy the 2nd half.
Chart shows that for the last 3 years, it has gone up and to the right despite some volatility. If you like the name, you just have to simply buy it. Maybe take half a position and not even worry about it, and then look for an opportunity to buy the 2nd half.
WAIT
WAIT
September 12, 2017
This had a good earnings beat and the stock did extremely well. He would suggest there is a little froth in it at the moment, but doesn’t think it is terribly valued. Any time anything has really shot up like this, it has to consolidate. If the earnings can catch up a little, with the valuation, it is probably approaching 20X PE. Good growth and good company, but is a little ahead of itself. He would give it a little room to consolidate.
This had a good earnings beat and the stock did extremely well. He would suggest there is a little froth in it at the moment, but doesn’t think it is terribly valued. Any time anything has really shot up like this, it has to consolidate. If the earnings can catch up a little, with the valuation, it is probably approaching 20X PE. Good growth and good company, but is a little ahead of itself. He would give it a little room to consolidate.
PAST TOP PICK
PAST TOP PICK
August 21, 2017
(Top Pick Nov 14/16, Up 17.89%) They just bought Patheon. There is no end in sight as to the kind of acquisitions they can do.
(Top Pick Nov 14/16, Up 17.89%) They just bought Patheon. There is no end in sight as to the kind of acquisitions they can do.
TOP PICK
TOP PICK
November 14, 2016
Life sciences is the big theme here. There has been a lot of consolidation in the industry. They acquired FEI Corp, which was in electron microscopes and major mass spectrometry. This has analysis, chemical analysis so that you can do DNA testing. They have so many ins around the world, so it is really their offshore business outside of the US that is driving the growth forward. Dividend yield of 0.41%.
Life sciences is the big theme here. There has been a lot of consolidation in the industry. They acquired FEI Corp, which was in electron microscopes and major mass spectrometry. This has analysis, chemical analysis so that you can do DNA testing. They have so many ins around the world, so it is really their offshore business outside of the US that is driving the growth forward. Dividend yield of 0.41%.
Thermo Fisher Scientific(TMO-N) Rating
Ranking : 3 out of 5
Bullish - Buy Signals / Votes : 2
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 2
Total Signals / Votes : 4
Thermo Fisher Scientific(TMO-N) Frequently Asked Questions
What is Thermo Fisher Scientific stock symbol?
Thermo Fisher Scientific is a American stock, trading under the symbol TMO-N on the New York Stock Exchange (TMO). It is usually referred to as NYSE:TMO or TMO-N
Is Thermo Fisher Scientific a buy or a sell?
In the last year, 4 stock analysts published opinions about TMO-N. 2 analyst recommended to BUY the stock. 2 analyst recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Thermo Fisher Scientific.
Is Thermo Fisher Scientific a good investment or a top pick?
Thermo Fisher Scientific was recommended as a Top Pick by Gordon Reid on 2020-01-29. Read the latest stock experts ratings for Thermo Fisher Scientific.
Why is Thermo Fisher Scientific stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Thermo Fisher Scientific worth watching?
4 stock analysts on Stockchase covered Thermo Fisher Scientific In the last year. It is a trending stock that is worth watching.
What is Thermo Fisher Scientific stock price?
On 2020-04-08, Thermo Fisher Scientific (TMO-N) stock closed at a price of $307.15.
